Known targets — ChEMBL curated mechanism
AKT1AKT2AKT3PRKACAPRKACBPRKACGPRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Gsk-690693. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 14/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 7/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 1.00 |
| ▸ | PRKACA known ✓ | P17612 | 1/20 | 1.00 |
| ▸ | PRKACB known ✓ | P22694 | 1/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 1.00 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 16/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 15/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-690693 SCHEMBL310452 | 1.00 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Gsk-690693 SCHEMBL29387832 | 1.00 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487696 | 0.96 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL21994179 | 0.93 | AKT1 (0.86) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL10053680 | 0.91 | AKT1 (0.91) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL15446768 | 0.91 | AKT1 (0.83) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL22930437 | 0.91 | AKT1 (0.85) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Hydrochloric Acid SCHEMBL690160 | 0.90 | AKT1 (0.90) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL18357231 | 0.89 | AKT1 (0.81) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13693040 | 0.89 | AKT1 (0.80) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205286-A1 | Methods and Compositions for Treating Autophagy Related Disease States and Conditions Utilizing AMPK Activation | UNM RAINFOREST INNOVATIONS (US) | 2021-07-08 | — | — | US | claimed |
| EP-2841075-B1 | AGENTS AND METHODS FOR TREATING AND PREVENTING SEBORRHEIC KERATOSIS | MASSACHUSETTS GEN HOSPITAL (US) | 2020-03-18 | — | — | EP | claimed |
| US-20150254400-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-10 | — | — | US | claimed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| EP-4714966-A2 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | Cero Therapeutics Holdings, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | NOVARTIS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | AKT1 4727/4885AKT2 4012/4885AKT3 3919/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | AKT1 2362/4885AKT2 1958/4885AKT3 1694/4885 |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | AKT1 2457/4885AKT2 2017/4885AKT3 3014/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885AKT2 3/4885AKT3 8/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885AKT2 3/4885AKT3 8/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | AKT1 1581/4885AKT2 1364/4885AKT3 2330/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | AKT1 4727/4885AKT2 4012/4885AKT3 3919/4885 |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CD47, TNFSF10, CD2 | AKT1 2751/4885AKT2 2736/4885AKT3 1856/4885 |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | EGFR, IGSF11, IGLV6-57 | AKT1 1342/4885AKT2 1280/4885AKT3 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.